ISRG is 67% below fair value, trading below its buy zone — an even more attractive entry for accumulation.
QuantHub Research: Investment Thesis
Investing Phase
Intuitive Surgical, Inc. operates in the healthcare sector, specializing in medical devices with a strong focus on robotic-assisted surgery systems. The company demonstrates high business quality with a durable competitive moat supported by a 17.0% return on equity, robust gross margin of 66.3%, and solid operating margin of 30.5%. Revenue and earnings growth in the most recent quarter were impressive at 23.0% and 17.6% respectively, indicating strong demand and operational efficiency. Valuation metrics such as a P/E trailing and forward of 46.47 and EV/EBITDA of 31.42 suggest the stock is fairly priced relative to its five-year history, supported by a fair value estimate of $564.01 which implies a 45.0% upside. The current market cap stands at approximately $5.06 billion with a price of $388.97, reflecting a premium valuation justified by the company’s growth prospects and strong margins. Analyst consensus rates the stock as a Strong Buy, reinforcing confidence in its future performance.
The stock trades at a premium P/E of 46.47 and EV/EBITDA of 31.42, reflecting high growth expectations. Despite this, the valuation is considered fair based on the company's five-year history and strong recent revenue growth of 23.0% in the most recent quarter. Analyst consensus remains bullish with a Strong Buy rating, but the absence of a consensus price target suggests some uncertainty or variability in future estimates. The 45% upside to the fair value estimate indicates room for appreciation, balancing the high multiples.
12–18 Month Outlook
In 18 months, Intuitive Surgical is expected to continue scaling its revenue driven by strong adoption of its robotic surgery platforms and recurring instrument sales. While growth remains robust, the high valuation multiples suggest limited near-term upside without further acceleration in earnings growth. The company’s leadership and competitive moat should sustain market share, but investors should monitor potential margin pressures and competitive dynamics.
Bull vs Bear
Bull Case
The company reported 23.0% revenue growth in the most recent quarter, signaling strong demand for its robotic surgery systems.
Intuitive Surgical maintains a high gross margin of 66.3%, demonstrating operational efficiency and pricing power.
A 17.0% return on equity reflects effective capital utilization and profitability.
The fair value estimate of $564.01 implies a 45.0% upside from the current price, indicating undervaluation relative to intrinsic worth.
Analyst consensus rates the stock as a Strong Buy, supporting positive market sentiment.
Bear Case
The stock trades at a high P/E of 46.47 and P/FCF of 48.6, which may limit upside if growth slows.
The company faces competitive pressure from other medical device firms such as Medtronic and Stryker, which could erode market share.
High valuation multiples increase vulnerability to market corrections or earnings disappointments.
Growth rates, while strong in the most recent quarter, may not be sustainable over the long term given the maturity of the robotic surgery market.
Any regulatory changes or reimbursement challenges in healthcare could negatively impact profitability.
Leadership & Competitive Position
Gary S. Guthart
Tenure10 yrs
Beats guidance75% of qtrs
Capital allocationGood
Gary Guthart has led Intuitive Surgical for a decade, overseeing consistent revenue growth and margin expansion. His background in engineering and prior leadership roles within the company have contributed to steady execution and innovation in robotic surgery.
Competitive Moat
stable
intangible assetsswitching costsnetwork effects
Intuitive Surgical holds a dominant position in the robotic-assisted surgery market with a significant share, benefiting from a strong installed base and surgeon familiarity.
Competitors: Medtronic (MDT), Stryker (SYK)
Disruption: Medium due to emerging technologies and potential new entrants in robotic surgery.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
46.47x
59.43x
59.43x
45.67x
78.93x
P/S
13.02x
15.87x
15.74x
9.43x
18.91x
P/FCF
48.6x
84.05x
74.29x
40.86x
203.07x
P/S 13.02x vs 5yr range 9.43-18.91x (P25=13.0x, median=15.74x, P75=17.32x)
Price Outlook (5-Year)
Bear
$451
6.0%/yr
Base
$564
10.8%/yr
fair value
Bull
$677
14.9%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Changes in healthcare regulations or reimbursement policies could adversely affect sales and profitability.
Competitive Pressure
medium
Rival firms like Medtronic and Stryker are investing in robotic surgery technologies, which could erode Intuitive Surgical’s market share.
Valuation Risk
medium
High valuation multiples increase the risk of price correction if growth expectations are not met.
Growth Engines
Robotic Surgery Systemsscaling
The total addressable market for robotic-assisted surgery is expanding as hospitals adopt advanced technologies to improve surgical outcomes and efficiency.
Surgical Instruments & Accessoriesscaling
Recurring revenue from instruments and accessories supports steady growth as installed base expands.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is ISRG undervalued?
Yes, ISRG appears undervalued at the current price of $337.50, trading below our fair value estimate of $564.01 (+67% upside). QuantHub considers this a buy zone.
What is ISRG's fair value?
QuantHub Research estimates ISRG's fair value at $564.01 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for ISRG?
Regulatory Changes: Changes in healthcare regulations or reimbursement policies could adversely affect sales and profitability. Competitive Pressure: Rival firms like Medtronic and Stryker are investing in robotic surgery technologies, which could erode Intuitive Surgical’s market share. Valuation Risk: High valuation multiples increase the risk of price correction if growth expectations are not met.
What is the bull case for ISRG?
The company reported 23.0% revenue growth in the most recent quarter, signaling strong demand for its robotic surgery systems. Intuitive Surgical maintains a high gross margin of 66.3%, demonstrating operational efficiency and pricing power. A 17.0% return on equity reflects effective capital utilization and profitability. The fair value estimate of $564.01 implies a 45.0% upside from the current price, indicating undervaluation relative to intrinsic worth. Analyst consensus rates the stock as a